Evolus, Inc. (0K16.L)
USD 14.58
(0.16%)
USD 14.58
(0.16%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 140.52 Million USD | 46.01% |
| 2022 | 92.72 Million USD | 65.18% |
| 2021 | 56.13 Million USD | 46.8% |
| 2020 | 38.24 Million USD | 42.1% |
| 2019 | 26.91 Million USD | 299111.11% |
| 2018 | -9000.00 USD | 95.87% |
| 2017 | -218 Thousand USD | 33.13% |
| 2016 | -326 Thousand USD | 21.63% |
| 2015 | -416 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 39.85 Million USD | -1.24% |
| 2024 Q2 | 46.4 Million USD | 16.43% |
| 2023 FY | 135.39 Million USD | 46.01% |
| 2023 Q2 | 34.63 Million USD | 17.11% |
| 2023 Q1 | 29.57 Million USD | -2.32% |
| 2023 Q3 | 33.89 Million USD | -2.14% |
| 2023 Q4 | 40.35 Million USD | 19.07% |
| 2022 Q2 | 21.34 Million USD | 3.11% |
| 2022 Q4 | 30.27 Million USD | 48.35% |
| 2022 Q3 | 20.4 Million USD | -4.38% |
| 2022 FY | 92.72 Million USD | 65.18% |
| 2022 Q1 | 20.7 Million USD | 9.97% |
| 2021 Q1 | 7.33 Million USD | -44.86% |
| 2021 Q2 | 14.79 Million USD | 101.77% |
| 2021 Q3 | 15.18 Million USD | 2.64% |
| 2021 Q4 | 18.82 Million USD | 23.94% |
| 2021 FY | 56.13 Million USD | 46.8% |
| 2020 Q2 | 5.85 Million USD | -6.68% |
| 2020 FY | 38.24 Million USD | 42.1% |
| 2020 Q3 | 12.8 Million USD | 118.62% |
| 2020 Q4 | 13.29 Million USD | 3.84% |
| 2020 Q1 | 6.27 Million USD | -60.3% |
| 2019 Q3 | 9.44 Million USD | 472.32% |
| 2019 FY | 26.91 Million USD | 299111.11% |
| 2019 Q4 | 15.81 Million USD | 67.33% |
| 2019 Q2 | 1.65 Million USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | -9000.00 USD | 95.87% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | -218 Thousand USD | 33.13% |
| 2017 Q4 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | -326 Thousand USD | 21.63% |
| 2015 FY | -416 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 241.192% |
| Dynavax Technologies Corporation | 182.11 Million USD | 22.838% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -849.885% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 99.47% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 73.169% |
| Perrigo Company plc | 1.68 Billion USD | 91.637% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 44996.486% |
| Illumina, Inc. | 2.74 Billion USD | 94.879% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 99.077% |
| Nektar Therapeutics | 53.47 Million USD | -162.773% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 1569.015% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 97.318% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -1299.383% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 813.366% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 92.621% |
| Waters Corporation | 1.76 Billion USD | 92.021% |
| Biogen Inc. | 7.3 Billion USD | 98.076% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 410.041% |
| Adicet Bio, Inc. | -6.09 Million USD | 2404.46% |
| bluebird bio, Inc. | -4.03 Million USD | 3586.998% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 264.906% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -92.325% |
| FibroGen, Inc. | 128.9 Million USD | -9.016% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 95.944% |
| Homology Medicines, Inc. | -7.22 Million USD | 2043.92% |
| Geron Corporation | -123.5 Million USD | 213.783% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 90.742% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 550.871% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 61.184% |
| Myriad Genetics, Inc. | 476.4 Million USD | 70.503% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 98.757% |
| OPKO Health, Inc. | 318.12 Million USD | 55.827% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 48225.342% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 135.238% |
| Zoetis Inc. | 5.83 Billion USD | 97.591% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -46431.788% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 93.521% |
| Exelixis, Inc. | 1.75 Billion USD | 92.005% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 98.367% |
| uniQure N.V. | 2.21 Million USD | -6244.289% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 46478.218% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 42.533% |
| Verastem, Inc. | -62 Thousand USD | 226754.839% |
| Imunon, Inc. | -720 Thousand USD | 19617.364% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 81.949% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 87.143% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 92.393% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 70.471% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 77.936% |
| TG Therapeutics, Inc. | 219.1 Million USD | 35.865% |
| Blueprint Medicines Corporation | 236.58 Million USD | 40.602% |
| Insmed Incorporated | 239.63 Million USD | 41.358% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -711.398% |
| Incyte Corporation | 3.44 Billion USD | 95.916% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 59.138% |